Valve Solutions

With a commitment to advancing innovative technology to ensure people living with structural heart diseases have safe and effective treatment options, Abbott was the first to develop minimally invasive transcatheter edge-to-edge repair (TEER*) therapy for patients with mitral regurgitation (MR) and tricuspid regurgitation (TR), and reimagined the minimally invasive treatment of aortic stenosis.


*TEER is also referred to TMVr (Transcatheter Mitral Valve Repair)

MitraClip™ TEER Therapy

MitraClip™ Transcatheter Edge-to-Edge Repair (TEER) procedure is a minimally invasive treatment option, uniquely designed for the mitral valve, for select patients with primary or secondary MR. As the first TEER therapy recommended by ACC/AHA1 and ESC/EACTS2-3 guidelines and by ASPC Recommendation,4 MitraClip is the only tailored therapy with over 18+ years of clinical experience and more than 150,000 patients treated worldwide,5 allowing physicians to treat more patients with more options.

Navitor™ TAVI System

Advancing the forefront of innovative design, the Navitor™ Transcatheter Aortic Valve Implantation (TAVI) System brings together smart PVL-sealing technology, exceptional single-digit gradients,6 stable deployment, accurate valve placement and uncompromised coronary access to achieve excellent clinical outcomes.

Portico™ with FlexNav™ TAVI System

Portico™ with FlexNav™ Transcatheter Aortic Valve Implantation (TAVI) System offers patients with aortic stenosis a minimally invasive treatment option. The Portico™ valve is the first fully resheathable,* repositionable,* and retrievable* valve, while the FlexNav™ delivery system offers remarkable deliverability and exceptionally smooth tracking to treat every TAVI case.7-9

*Until fully deployed

TriClip™ TEER System

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) is a minimally invasive treatment option for patients with symptomatic severe Tricuspid Regurgitation (TR). TriClip TEER offers unmatched stability, precision, and control for the unique challenges of the tricuspid anatomy to achieve sustained, clinically significant improvements in the lives of TR patients.


  1. Heidenreich PA, et al. "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association. Joint Committee on Clinical Practice Guidelines." J Am Coll Cardiol. Apr 01,2022. Epublished DOI: 10.1016/j.jacc.2021.12.012.
  2. Vahanian A, Beyersdorf F, Praz F, et al., ESC/EACTS Scientific Document Group, 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 561–632,
  3. McDonagh TA, Metra M, Adamo M, et al., ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726,
  4. Yeo KK, Tan JWC, Muller DW, et al. Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation. Eur Cardiol. 2021;16:e25. Published 2021 Jun 1. doi:10.15420/ecr.2021.01
  5. Data on File at Abbott.
  6. Smith, D. One-year clinical trial results with a next-generation aortic transcatheter heart valve. Presented at: EuroPCR conference; May 17-20, 2022.
  7. Portico Transfemoral Transcatheter Aortic Valve Implantation System Instructions for Use.
  8. Abbott data on file 90158807.
  9. Abbott data on file. Portico Transcatheter Aortic Valve Implantation System CE Mark 585003.

MAT-2304768 v1.0